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Introduction
Endometrial cancer is most commonly diagnosed at an early stage and most women are cured with surgery alone. 1 Adjuvant treatment for early stage endometrial cancer is based on risk factors, such as histological grade, myometrial invasion, age, and lymph-vascular space invasion. [2] [3] [4] The PORTEC-2 trial 5, 6 showed the effi cacy of vaginal brachytherapy in reducing vaginal recurrence of endometrial cancer in women with high-intermediate-risk endometrial cancer. About 15% of all patients with endometrial cancer have high-risk disease (classifi ed as stage I grade 3 cancer with deep invasion or with substantial lymph-vascular space invasion, stage II or III cancer, or cancer with non-endometrioid histology). 1 Higher incidence of distant metastases and endometrial cancer-related deaths has been reported for these patients. [7] [8] [9] [10] Serous and clear cell endometrial cancer are histological subtypes with poorer prognosis because of their high risk of metastasis, but when diagnosed at an early stage seem to have similar survival rates to grade 3 endometrioid endometrial cancer. 11 Pelvic external beam radiotherapy has been the standard adjuvant treatment for women with high-risk endometrial cancer for several decades. Randomised trials 12, 13 comparing adjuvant chemotherapy with external beam radiotherapy have shown similar rates of relapse and survival. Because increased pelvic relapse has been reported with adjuvant chemotherapy alone, use of pelvic radiotherapy combined with adjuvant chemotherapy has been advocated. 14, 15 The RTOG9708 phase 2 trial 16 investigated a combination of external beam radiotherapy with two cycles of cisplatin, followed by four cycles of cisplatin-paclitaxel in 46 women with high-risk endometrial cancer. 4-year overall survival was 85% and disease-free survival was 81%, and acceptable toxicity was reported. The randomised NSGO-EC-9501/EORTC-55991 trial compared external beam radiotherapy alone with external beam radiotherapy and four cycles of platinum-based chemotherapy. This trial was published in a pooled analysis with the MaNGO ILIADE-III trial 17 with a combined total of 534 patients, and showed statistically signifi cantly improved progression-free survival with the addition of chemotherapy. None of these trials have reported detailed toxicity or quality of life data for chemoradiotherapy in endometrial cancer. Establishing both the benefi t of more intensive adjuvant treatment and the eff ect in terms of added morbidity and eff ect on health-related quality of life are essential.
We initiated the international PORTEC-3 trial to investigate survival benefi t and toxicities of chemotherapy
Research in context
Evidence before this study We searched PubMed between Jan 1, 1980, and Dec 31, 2006 , with the terms "endometrial cancer" AND "radiation therapy" AND "chemotherapy" AND "toxicity" AND "quality of life", with a fi lter for clinical trials, clinical studies, and multicentre studies. We identifi ed eight relevant publications, mostly small studies of which most used a sequential schedule with various chemotherapy drugs, and only two trials assessed combined chemotherapy and radiotherapy. The studies only very briefl y mentioned acute toxicities and no long-term data for adverse events were available. Studies which compared radiotherapy with chemotherapy did not report on quality of life and only limited data for adverse events were available. The phase 2 RTOG 9708 trial, which assessed toxicity of the combined chemotherapy and radiotherapy schedule, and on which the PORTEC-3 treatment schedule was based, reported a 98% completion rate among 46 patients. Acute grade 3 adverse events were reported in 12 (27%) patients and grade 4 adverse events in one (2%) patient during concurrent chemoradiotherapy and in nine patients (21%) and 26 patients (62%) during adjuvant chemotherapy. For chronic toxicities, grade 3 adverse events were found in seven (16%) patients and grade 4 adverse events were found in two (5%) patients; no quality of life data were available.
Added value of this study
To our knowledge, this is the fi rst randomised study reporting adverse events and quality of life of this combined chemotherapy and radiotherapy schedule. We assessed the toxicity and quality of life of patients with high-risk endometrial cancer treated in the international randomised PORTEC-3 trial with pelvic radiotherapy alone or the combination of radiotherapy with concurrent (cisplatin) and adjuvant (carboplatin-paclitaxel) chemotherapy. The combination of chemotherapy and radiotherapy had signifi cant eff ect on adverse events and quality of life during and after treatment. However, rapid recovery occurred between 6-12 months after randomisation, without diff erence in grade 3 adverse events at 12 and 24 months. Grade 2 neurological adverse events persisted in 10% of patients in the chemoradiotherapy group versus <1% of patients in the radiotherapy group alone, with 25% of patients in the chemoradiotherapy group reporting "quite a bit" or "very much" tingling or numbness.
Implications of all the available evidence
Combined adjuvant chemoradiotherapy for women with high-risk endometrial cancer is feasible, with increased rates of adverse events and a higher eff ect on health-related quality of life during and after treatment. Persisting neurological symptoms were the only adverse event that diff ered signifi cantly between groups 12 months after randomisation. Final analysis of the PORTEC-3 trial is awaited to determine the trade-off of the survival benefi t versus eff ect on quality of life of added chemotherapy in women with high-risk endometrial cancer.
combined with external beam radiotherapy compared with external beam radiotherapy alone for high-risk endometrial cancer. Final analysis of overall survival and failure-free survival is awaited, as the required number of events has not yet been reached. We did this analysis to establish and compare adverse events and patientreported symptoms and health-related quality of life in women with high-risk endometrial cancer treated in PORTEC-3.
Methods

Study design and participants
PORTEC-3 was a multicentre, open-label, randomised intergroup trial led by the Dutch Gynaecological Oncology Group. Patients were enrolled in the study by the radiation oncologists from the participating centres in the following international participating groups: the Medical Research Council and the National Cancer Research Institute (UK), the Australia New Zealand Gynaecological Oncology Group (Australia and New Zealand), Mario Negri Gynecologic Oncology group (Italy), Fedegyn (France) and National Cancer Institute of Canada Clinical Trials Group (Canada).
Patients were eligible for inclusion in this trial if they had International Federation of Gynecology and Obstetrics 2009 categorised stage IA grade 3 endometrial carcinoma with myometrial invasion and with documented lymph-vascular space invasion; stage IB grade 3; stage II, stage IIIA, or IIIC (or IIIB if parametrial invasion only); serous or clear cell histology with stage IA (with invasion), IB, II, or III. Eligible patients also had to have adequate WHO performance scores (WHO score 0-2); bone marrow (white blood cell count ≥3·0 cells × 10⁹/L, platelets ≥100 × 10⁹/L); liver function (bilirubin ≤1·5 × upper limit of normal [ULN], aspartate aminotransferase concentration ≤2·5 × ULN, or alanine aminotransferase concentration ≤2·5 × ULN); and kidney function (creatinine clearance >60 mL/min calculated according to Cockroft 18 or >50 mL/min EDTA clearance) and be aged older than 18 years. Exclusion criteria were having uterine sarcoma, previous malignancy less than 10 years ago, receipt of previous pelvic radiotherapy, hormonal or chemotherapy, gross cervical involvement with radical hysterectomy, infl ammatory bowel disease, residual macroscopic tumour, impaired renal or cardiac function, neuropathy grade 2 or worse, hearing impairment grade 3 or worse, or congenital hearing disorder.
Surgery comprised of total abdominal or laparoscopic hysterectomy with bilateral salpingo-oophorectomy. Lymphadenectomy was left at the discretion of the participating centres. For serous or clear cell carcinoma, staging including omentectomy; peritoneal biopsies and lymph node sampling were recommended. Upfront central pathology review was undertaken by the reference gynaecological pathologists of the participating groups to confi rm fi nal eligibility for the study.
Written informed consent was obtained from all patients. The protocol was approved by the Dutch Cancer Society, and the ethics committees of the participating groups or centres. Participating groups obtained their institutional review board and ethics approvals and were funded by separate grants. The protocol is available online.
Randomisation and masking
Patients were randomly allocated (1:1) to receive either chemoradiotherapy or radiotherapy alone. Treatment was allocated with a biased coin minimisation procedure, with stratifi cation according to participating centre, lymphadenectomy (yes or no), stage, and histological type. The outcome of the allocation was computer generated and not predictable by the investigators. Patients were registered and randomised by the participating group's data centres and treatment was assigned with a web-based application. The trial number and assigned treatment were generated immediately by the randomisation programme and confi rmed by email to the investigators. Participants and investigators were not masked to treatment allocation.
Procedures
Pelvic radiotherapy was given in both treatment groups (48·6 Gy in 1·8 Gy fractions, fi ve times a week for 5·5 weeks). The clinical target volume included the proximal vagina, parametrial tissues, and internal, external, and common iliac lymph node regions up to the upper S1 level (the level of promontory). The clinical target volume was extended for lymph node involvement. In case of cervical involvement, a brachytherapy boost was given. Treatment had to be started preferably within 4-6 weeks after surgery, but no later than 8 weeks after surgery. Treatment breaks were avoided and could not exceed 2 days, overall treatment time for radiotherapy could not exceed 50 days.
Patients in the chemoradiotherapy group received two cycles of cisplatin 50 mg/m² in the fi rst and fourth week of radiotherapy, followed by four cycles of carboplatin area under the curve (AUC) 5 and paclitaxel 175 mg/m² at 21-day intervals (and a 28-day interval between the second concurrent and fi rst adjuvant cycle). This schedule was based on the RTOG9708 trial, 16 with substitution of cisplatin with carboplatin in the adjuvant phase. In the event of haematological, renal, or other toxicities, cisplatin was postponed for 1 week. If recovery required more than 1 week or in the case of neurological adverse events of grade 2 or worse, cisplatin was discontinued. Carboplatin was postponed or stopped in the case of severe haematological toxicity. Carboplatin dose was reduced to AUC 4 if recovery to grade 1 was attained at two weeks. Paclitaxel was postponed if grade 2 neuropathy was reported and stopped if recovery exceeded 1 week or grade 3 neuropathy developed. After recovery or reduction to grade 1 adverse events, paclitaxel dose was reduced to 135 mg/m². Carboplatin and paclitaxel were delayed for other grade 3-4 toxicities, and discontinued if there was no recovery or reduction to grade 1 adverse events. Patients were assessed every 3 months for the fi rst 24 months, and every 6 months up to 5 years. Long-term outcome evaluation at 7 and 10 years was obtained, preferably by follow-up visits, or by information from their general practitioner. At each follow-up visit, a patient history with emphasis on treatment-related morbidity, and physical and pelvic examination was done. Chest radiograph, blood count, and chemistry tests (including Ca-125) were obtained once a year, up to 5 years after randomisation. Toxicity was graded with the Common Terminology Criteria for Adverse Events version 3.0 and was assessed at baseline (after surgery), completion of radiotherapy, at each chemotherapy cycle, and at 6-month follow-up intervals from randomisation until 5 years and at 7 and 10 years. Health-related quality of life questionnaires were completed at baseline after surgery and after completion of radiotherapy, at 6-month intervals from randomisation until 24 months, and at 36 and 60 months. Health-related quality of life was assessed with the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30, version 3.0). 19 As the EORTC endometrial module was not yet available, the cervix 24 (CX24) module was used, with added chemotherapy and neuropathy subscales from the ovarian 28 (OV28) module. 20, 21 Higher scores on functional and global health-related quality of life scales represented better levels of functioning. On the symptom subscales, higher scores refl ected higher levels of symptoms.
All adverse events were graded and adverse events of grade 2 or worse were reported on case record forms, irrespective of the relation with study treatment. For mild (grade 1) toxicities, the patient-reported health-related quality of life symptoms were used. Serious adverse events were reported within 24 h, specifying adverse event grade and relation to study treatment. Time from randomisation was used to compare severity and duration of toxicities between the treatment groups; importantly, the 6-month timepoint was about 1 month after completion of chemotherapy in the chemoradiotherapy group.
Outcomes
Primary endpoints were overall survival and failure-free survival, with failure defi ned as any relapse or death related to endometrial carcinoma. Secondary endpoints were treatment-related toxicity, health-related quality of life, and pelvic or distant relapse.
Statistical analysis
The PORTEC-3 trial was powered (80%) to detect a diff erence of 10% (HR 0·67) in 5-year overall survival (65% to 75%); for this, 198 events were required, and a minimum of 655 patients. The analysis plan for the second primary endpoint failure-free survival will be added in an amendment to the trial protocol. Primary and secondary outcomes not involving toxicity or health-related quality of life were analysed by intention to treat. Safety outcomes were assessed in all patients who received at least one cycle of chemotherapy and 1 week of radiotherapy (in the chemoradiotherapy group) and 1 week of radiotherapy (in the radiotherapy alone group). Although no specifi c power calculations were done for the toxicity and health-related quality of life analysis, the minimum required number of 655 patients ensured suffi cient power to detect clinically relevant diff erences. Toxicity and quality of life were analysed according to treatment received.
Formal tests for the diff erences in relapse and survival rates between the two groups were done with the Kaplan-Meier method, the log-rank test, and Cox regression analysis. The median follow-up of all patients was estimated by the inverse Kaplan-Meier method. We measured toxicity at baseline, at completion of radiotherapy, every cycle of concurrent and adjuvant chemotherapy, and 6, 12, 18, and 24 months; quality of life was measured at baseline, completion of radiotherapy, and 6, 12, 18, and 24 months after randomisation. During follow-up, toxicity and quality of life forms completed within a 3-month window before or after the designated timepoint were included. The time during treatment was defi ned as all toxicity forms related to radiotherapy and all cycles of concurrent and adjuvant chemotherapy.
Criteria to be removed from the analysis were ineligibility or withdrawal of informed consent before the start of treatment. Patients were evaluable for health-related quality of life analysis if they had completed baseline and at least one follow-up form. Missing data for patients were handled as missing-at-random, assuming that missing data was not related to the values of the unobserved variables. This is an assumption that is not possible to verify statistically. 22 The prevalence of toxicity graded according to the Common Terminology Criteria for Adverse Events version 3.0 was calculated at each timepoint. Per adverse event, the maximum grade per patient was calculated (worst ever by patient). The maximum grade over the entire course of therapy and follow-up for any adverse events and for the individual patient was used as a summary of toxicity. Fisher's Exact test was used to compare toxicity between the two treatment groups. A prespecifi ed health-related quality of life analysis was done according to the EORTC Quality of Life Group guidelines. 23 Baseline scores of both treatment groups were compared with a t test, or Armitage trend test for single items. A linear mixed model was used to obtain estimates of the EORTC QLQ-C30, CX24, and OV28 subscales at each of the timepoints, with patient as random eff ect and time (categorical), treatment, and their interaction between time and treatment as fi xed eff ects. Single items were analysed with (binary) logistic regression with random eff ect, combining scores of 1-2 ("not at all" and "a little") and 3-4 ("quite a bit" and "very much"). The diff erence in health-related quality of life between the groups over time was tested by a joint Wald test of all treatment-by-time interaction in the linear or logistic mixed model. To guard against false-positive results because of multiple testing, a two-sided p value of less than or equal to 0·01 was considered statistically signifi cant.
Guidelines for the interpretation of clinically relevant changes to EORTC QLQ-C30 scores were applied. 24, 25 For scales not included in the guidelines, changes were assessed according to Osoba and colleagues. 26 Statistical analyses were done with SPSS, version 20.0, and R statistical software, version 3.2.1.
A Data and Safety Monitoring Board oversaw the study. After discussion within the trial management group and with approval of the Data and Safety Monitoring Board, the decision was made to submit for publication. The study was closed on Dec 20, 2013, after achieving complete accrual; follow-up is continuing. This trial is registered with ISRCTN.com, number ISRCTN14387080, and with ClinicalTrials.gov, number NCT00411138.
Role of the funding source
The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The central data manager (KWV-A), the principal investigator (CLC) and associated investigators (SMdB, RAN), and trial statistician (HP) had full access to the data. The Dutch Cancer Society Scientifi c Review Board approved the trial design. The corresponding author and chief investigator had full access to all of the data and the fi nal responsibility to submit for publication.
Results
Between Sept 15, 2006 , and Dec 20, 2013, we recruited 686 patients to the PORTEC-3 trial recruited. Of these patients, 13 did not meet inclusion criteria (fi gure 1). Reasons for exclusion were diff erent stage, macroscopic residual disease, low creatinine clearance, impaired hearing (≥grade 3), or diff erent histological type. Another 13 patients withdrew their informed consent immediately after randomisation and were excluded from this analysis, leaving 660 patients (330 in each group) for intention-to-treat analysis. Seven (1%) of 660 patients refused the allocated treatment (fi ve in the chemoradiotherapy group and two in the radiotherapy alone group) and switched to the other treatment group (fi gure 1). For analysis of toxicity and health-related quality of life these seven patients were assessed by treatment received, resulting in 327 patients in the chemoradiotherapy group and 333 patients in the radiotherapy alone group. Median follow-up at the time of analysis for all patients was 42·3 months (IQR 25·8-55·1); 42·1 months (25·7-54·7) in the chemoradiotherapy group and 42·4 months (27·1-55·4) in the radiotherapy alone group. With ongoing follow-up, 487 (74%) patients (240 in the chemoradiotherapy group and 247 in the radiotherapy alone group) had reached the 2-year timepoint by the time of this analysis.
Patient characteristics were well balanced between the chemoradiotherapy and radiotherapy alone groups (table 1). Lymphadenectomy was performed in 203 (62%) in the chemoradiotherapy group and in 205 (62%) patients in the radiotherapy alone group. Radiotherapy was discontinued by one (<1%) patient who received chemoradiotherapy because of disease progression and by fi ve (2%) patients who received radiotherapy alone because of toxicity (n=4) and an accidental fall with femur fracture (n=1). A brachytherapy boost was given in 149 (46%) of 327 patients in the chemoradiotherapy group and 156 (47%) of 333 patients in the radiotherapy alone group. Treatment completion details are shown in table 1. Chemotherapy was discontinued in 61 (19%) patients because of drug-related toxicity in 31 (9%) patients, patient decision in 20 (6%) patients, disease progression in seven (2%) patients, or for other reasons in three (1%) patients. Dose reductions were reported if the dose was reduced by more than 10%. At least one dose reduction of cisplatin (to 40 mg/m²) was recorded for fi ve (2%) patients, of carboplatin (from AUC 5 to AUC 4) for 22 (7%) patients, and of paclitaxel (from 175 mg/m² to 135 mg/m²) for 34 patients (10%). Analysis of primary outcomes is ongoing and will be reported in a future publication.
For 570 (86%) of 660 patients, a baseline questionnaire and at least one follow-up questionnaire was received, 292 for the chemoradiotherapy group and 278 in the . WHO performance score was diff erent between those who responded to the questionnaire and those who did not, with WHO 0-1 recorded in 565 (99%) of 570 patients who responded versus 85 (94%) of 90 patients who did not respond, and WHO score of 2 or more in fi ve (1%) patients who responded versus fi ve (6%) patients who did not respond (p=0·007).
No other diff erences were seen in patient characteristics between responders and non-responders (data not shown). 89% of the responders completed all items of the EORTC QLQ-C30 in the returned questionnaires, 80% completed all items of the CX24 subscale, 92% completed all non-sexual items, and 91% of the responders completed all items of the OV28 subscale. Adverse event incidence during and after treatment is summarised in table 2. A comprehensive list of adverse events is provided in the appendix (p 4). At baseline, no signifi cant diff erences in adverse events were recorded between groups. Baseline grade 2 adverse events were reported for 109 (33%) of 327 patients who received chemoradiotherapy and 93 (29%) of 326 patients who received radiotherapy alone, and grade 3-4 toxicities were reported in 33 (10%) patients who received chemoradiotherapy and 28 (9%) patients who received radiotherapy alone. No deaths occurred during treatment; two patients (one in each group) died shortly after treatment: one patient in the chemoradiotherapy group died from pneumonia after surgery for bowel obstruction because of adhesions; one elderly patient in the radiotherapy alone group died 3 weeks after radiotherapy because of pneumonia and subsequent multiorgan failure. The death of both patients was not related to the study treatment as reported by the treating physician.
During the study, including whole treatment and follow-up period, 89 (27%) of 327 patients in the chemoradiotherapy group versus 154 (47%) of 326 patients in the radiotherapy alone group had a maximum toxicity of grade 2 adverse events. Grade 3 adverse events or worse were reported for 229 (70%) of 327 patients in the chemoradiotherapy group versus 112 (34%) of 326 patients in the radiotherapy alone group (fi gure 2). During treatment, grade 2 or worse adverse events were found in 309 (94%) of 327 patients Results of the EORTC QLQ-C30 functioning subscales and global health status, and mean scores for CX24 and OV28 subscales are summarised in table 3. All single symptom items are reported in appendix (p 7). During treatment, patients treated with chemoradiotherapy scored signifi cantly lower on most EORTC functioning scales; 10-20-point lower scores on physical, role, and social functioning, and global health status compared with patients treated with radiotherapy alone. However, rapid recovery was reported, and at 12 months physical functioning was the only signifi cant diff erence between the two treatment groups (fi gure 3).
The most frequently reported severe ("quite a bit" or "very much") symptoms at 6 months were tingling or numbness in 111 (52%) of 214 patients in the chemoradiotherapy group versus 15 (7%) of 209 patients in the radiotherapy alone group (p<0·0001), muscle or joint pain in 80 (37%) of 214 patients in the chemoradiotherapy group versus 45 (22%) of 207 patients in the radiotherapy alone group (p=0·002), fatigue in 66 (31%) of 210 patients versus 36 (17%) patients (p=0·0004), weakness in the arms or legs in 76 (36%) of 214 patients versus 24 (11%) of 209 patients (p<0·0001), and hair loss in 88 (44%) of 200 patients versus eight (4%) of 208 patients (p<0·0001), with events in the chemoradiotherapy group signifi cantly higher in all these cases. At 24 months, most diff erences had subsided and the most frequent symptoms did not diff er much from baseline (fi gure 4). Tingling or numbness was still signifi cantly higher in patients in the chemoradiotherapy group (48 [25%] of 194 vs 11 [6%] of 170 patients; p<0·0001).
Patient-reported lymphoedema did not diff er between the two treatment groups (appendix p 7). Severe lymphoedema was reported more frequently by patients who had undergone a lymphadenectomy (both treatment groups combined): 47 (17%) of 276 patients after lymphadenectomy versus 13 (8%) of 163 patients without lymphadenectomy at 12 months (p=0·01) and 38 (16%) of 237 patients versus 14 (11%) of 127 patients at 24 months (p=0·2). After lymphadenectomy, severe lymphoedema was reported by 18 (15%) of 120 patients in the chemoradiotherapy group and 20 (17%) of 117 patients in the radiotherapy alone group at 24 months (p=0·84), compared with seven (10%) of 69 patients and seven (12%) of 58 patients, respectively, who had no lympha denectomy (p=0·69; appendix, p 9). No signifi cant diff erences in sexual functioning score were seen between the treatment groups, measured according to CX24 (table 3) . Sexual activity was low in both groups, but was slightly higher in the radiotherapy alone group during treatment (p=0·006), and similar thereafter (see appendix p 8).
Discussion
This analysis of toxicity and 2-year health-related quality of life in the PORTEC-3 trial for women with high-risk endometrial cancer clearly shows that adjuvant chemotherapy given during and after pelvic radiotherapy causes signifi cantly higher incidence of severe adverse events and of patient-reported symptoms, and a decreased level of patient functioning and health-related quality of life compared with radiotherapy alone. However, rapid recovery was seen, with reduction of all incidence and grades of adverse events between 6 and 12 months after randomisation, and without signifi cant diff erences in grade 3 or worse adverse events at 12 and 24 months. The only remaining signifi cant diff erence in adverse events at 12 and 24 months was increased grade 2 or worse sensory neuropathy in the chemoradiotherapy group compared with the radiotherapy alone group (25 [10%] of 240 vs 1 [<1%] of 247), with health-related quality of life showing "quite a bit" or "very much" tingling or numbness reported by 25% of patients in the chemoradiotherapy group versus 6% of patients in the radiotherapy alone group. After 24 months, patients treated with chemoradiotherapy group still had slightly lower physical functioning scores, which might partly be because of their higher rate of peripheral neuropathy. Most functioning scores showed small remaining diff erences (0-6 points) in mean scores, which are of borderline clinical relevance according to the guidelines for interpretation of the EORTC QLQ-C30. 24, 25 Patients treated in the chemoradiotherapy group reported signifi cantly more tingling or numbness, muscle or joint pain, fatigue, weakness in the arms and legs, and hair loss at 6 months. All of these items, together with a longer treatment duration and more intense treatment because of the chemotherapy could be contributing to lower quality of life scores. The association between individual symptoms and overall quality of life will be a subject of further investigation.
The 6-month timepoint when most severe adverse events and worst quality of life were reported by patients receiving chemoradiotherapy was only 1 month after completion of chemotherapy, whereas patients treated with radiotherapy alone already had 4 months of recovery time. These results represent the toxicity profi les of the patients in the two treatment groups and provide a realistic view of the time with toxicity in the chemoradiotherapy group, which is of relevance for patient counselling when considering chemotherapy.
Data for the toxicity of chemotherapy in advanced or metastatic endometrial cancer are mainly available from the randomised trials 27 in which doxorubicin and cisplatin with or without paclitaxel were used. Incidence of sensory neuropathy in those trials during chemotherapy was signifi cantly higher than in the PORTEC-3 trial, with 27% of patients having grade 2 adverse events and 12% of patients having grade 3 neuropathy when treated with the doxorubicin, cisplatin, and paclitaxel triplet combination. Results of the randomised GOG-209 28 trial in which the triplet chemotherapy was compared with carboplatin-paclitaxel are pending, but an abstract reported similar effi cacy with a better toxicity profi le of carboplatin-paclitaxel (NCT00063999). The GOG-249 trial 29 compared pelvic radiotherapy alone with vaginal brachytherapy followed by three cycles of carboplatin and paclitaxel in patients with stage I-II endometrial cancer with high-intermediate-risk or high-risk features. First results at a median follow-up of 24 months showed no diff erences in recurrence-free and overall survival, with more acute toxicity in the chemotherapy group. Data for health-related quality of life are pending. Data for toxicity and health-related quality of life of women treated with carboplatin or paclitaxel chemotherapy are mainly available from fi rst-line therapy in ovarian cancer trials. Comparison is relevant, as patients with ovarian cancer are of similar age and have also had previous pelvic surgery, and the combination of radiation and chemotherapy was expected to be more toxic than chemotherapy alone. Ovarian cancer trials with a 3-weekly schema of carboplatin AUC6 and paclitaxel 175-180 mg/mL reported mainly grade 3-4 haematological toxicities, with similar grades of haematological toxicity and febrile neutropenia in the MITO-7 trial 30 compared with PORTEC-3, and higher grades reported in the JGOG-3016 trial. 31 Additionally with this 3-weekly schema, grade 3-4 sensory and motor neuropathy were reported in 6% and 4% respectively in JGOG 3016, compared with 7% and 1% in PORTEC-3, and 3% had any grade 3-4 neuropathy in the MITO-7 trial.
At 24 months after randomisation, patient-reported sensory neuropathy remained signifi cantly worse in the chemoradiotherapy group than in the radiotherapy alone group. A population-based study in ovarian cancer survivors reported peripheral neuropathy (as measured with EORTC-OV28) in 51% of patients treated with chemotherapy versus 27% of participants treated without chemotherapy. 32 Neuropathy is a common symptom in the general population, increasing with age and with the prevalence of diabetes. 33 Women with higher levels of neuropathy reported lower levels of functioning and quality of life, and more fatigue. 32 Completion rates for chemotherapy were 93% for cisplatin, 80% for carboplatin, and 72% for paclitaxel, with dose reductions in 7% of carboplatin and 10% of paclitaxel cycles. Completion was lower than in RTOG9708, 16 but refl ects clinical practice in a large multicentre trial. In MITO-7, 30 90% of the patients treated carboplatin-paclitaxel received all six cycles; but with dose reductions in 36%. No signifi cant diff erences were seen between the treatment groups in sexual functioning. Similar to health-related quality of life fi ndings in the PORTEC-1 and PORTEC-2 trials, baseline sexual activity just after surgery and during treatment was low, with improvement over time, but sexual activity in this elderly patient group remained lower compared with population data. 6 The current endometrial cancer module (EN24) was not yet available when the PORTEC-3 trial was designed. Therefore the CX24 module has been used with the subscale of chemotherapy from OV28, which has not been specifi cally tested for endometrial cancer. This could be a possible limitation to the study, although the EN24 module is very similar to CX24, with some of the same chemotherapy-related questions as in OV28 included. 34 PORTEC-3 assessed both physician-reported and patient-reported toxicities. Limited agreement between patient and physician reported scoring of toxicities has been shown, with signifi cant physician under-reporting of lower grade toxicities. 35 In the PORTEC-3 study, physicians were required to report grade 2 or worse adverse events to focus on more severe toxicities, and patient-reported outcomes were used for mild toxicities. Although patient-reported and physician-reported symptoms use diff erent scales, similar trends in types of symptoms over time were seen.
Both the PORTEC-3 trial and the GOG-258 trial used the same combined chemotherapy-radiotherapy schedule, but in comparison with radiotherapy alone and chemotherapy alone, respectively. The toxicity and health-related quality of life outcomes need to be considered in the light of fi nal survival data. If these trials were to show the combined treatment to be superior, future trials should focus on treatment schedules with least toxicity. For ovarian cancer, several trials have been done to compare diff erent (weekly) infusion schedules to achieve a balance between optimum therapy and acceptable toxicity. 30, 31 Overall, combined adjuvant chemotherapy and radiotherapy for high-risk endometrial cancer caused signifi cantly higher incidence of severe adverse events and reduced health-related quality of life during and after treatment compared with radiotherapy alone, but with rapid recovery. The most persisting and troublesome symptom was sensory neuropathy, rated as "quite a bit" or "very much" by 25% of patients at 24 months. This schedule of combined chemotherapy and radiotherapy is feasible, and these data are essential for patient counselling and shared decision making on adjuvant chemotherapy. The question remains whether the impact in terms of toxicities will be outweighed by an overall or failure-free survival benefi t. Final analysis of the PORTEC-3 and GOG258 trials are awaited, to determine the benefi t of chemoradiotherapy in women with high-risk endometrial cancer.
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